secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001213900-24-094155
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal raises $4.7M via warrant exercise; issues new warrants for additional shares
--------------------------------------------------------------------------------

- Exercised 285,715 existing warrants at reduced price of $16.50/share, generating ~$4.7M gross proceeds.
- Issued new Series A-1 and A-2 warrants each to purchase 285,715 shares at $16.50/share as inducement.
- Net proceeds to fund pivotal Phase 3 trial of tecarfarin and partnering activities.
- H.C. Wainwright & Co. served as placement agent; receives 7% cash fee and 18,571 placement agent warrants.
- New Series A-1 warrants expire in 5 years; Series A-2 expire 18 months after resale registration effective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/0001213900-24-094155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/ea0219768-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-094155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer